🧫
Ketamine in obstetric TRD patients
active
experiment
Created: 2026-04-10T22:47:07
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-565cb899-e9e9-40f6-be7f-73867944c11d
🧫 Experiment Protocol
Clinicaltreatment-resistant depressionpregnant and postpartum womenproposed
Clinical evaluation of ketamine and esketamine use in pregnant and postpartum women with treatment-resistant depression. This critical population study examined the safety and efficacy of NMDA receptor antagonists during pregnancy and the postpartum period, addressing the unique challenges of treating depression in women during reproductive years. The research considered maternal and fetal safety profiles, potential teratogenic effects, impacts on pregnancy outcomes, and the critical need for effective depression treatment during this vulnerable period when conventional treatments may be contraindicated or ineffective.
PRIMARY OUTCOME
maternal antidepressant efficacy and maternal-fetal safety
EXPECTED OUTCOMES
Effective depression treatment with acceptable maternal-fetal safety profile
SUCCESS CRITERIA
Antidepressant efficacy without significant maternal or fetal adverse outcomes
PROTOCOL
Careful administration of ketamine/esketamine with intensive maternal and fetal monitoring
Source: PMID 41935374 ↗
🧫 Experiment Extras
PATHWAY
NMDA receptor signaling
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.